INTRODUCTION {#s1}
============

Colorectal cancer (CRC) is the second most commonly diagnosed cancer worldwide \[[@R1]\]. CRC is one of the primary causes of cancer-related mortality. To date, the etiology of CRC is still unclear. Some environmental factors including diet, cigarette smoking, physical inactivity, and alcohol consumption, are considered to influence the risk of CRC \[[@R2]\]. Studies demonstrated that those environmental factors through the insulin pathway are significantly associated with the risk of CRC \[[@R3], [@R4]\]. Several researches provided evidence to support that insulin is associated with the risk of CRC \[[@R3], [@R4]\]. Some researchers reported that hyperinsulinaemia and type 2 diabetes influence the risk of colon cancer \[[@R5]\]. Animal research found that insulin enhances the growth of aberrant crypt foci, CRC precursor lesions, and increases the number and the size of the tumors \[[@R4]\].

Insulin receptor substrates (IRSs) are involved in insulin signaling pathway \[[@R6]\]. IRS-2 plays an important role in glucose metabolism, tumor progression, and metastasis \[[@R7]\]. A host of studies \[[@R8]--[@R12]\] investigated the association between IRS-2 gene rs1805097 polymorphism and CRC risk, but with conflicting findings. These conflicting and inconclusive results may due to clinical heterogeneity, diverse ethnic populations, different tumor types, and small sample sizes. Therefore, we performed a comprehensive meta-analysis to clarify the possible association between IRS-2 gene rs1805097 polymorphism and CRC risk.

RESULTS {#s2}
=======

Characteristics of the included studies {#s2_1}
---------------------------------------

We yielded a total of 51 citations after initial search. 33 citations were removed after removing duplicates and screening the titles and abstracts. 18 citations were selected for further full text review. 13 citations were excluded: 1 investigated other polymorphisms; 5 were about other diseases; 2 were meta-analyses. Finally, 5 citations \[[@R8]--[@R12]\] containing 6 studies (4,333 cases and 5,333 controls) were included in this meta-analysis. Selection for eligible studies included in this meta-analysis was presented in Figure [1](#F1){ref-type="fig"}. The characteristics of included studies are summarized in Table [1](#T1){ref-type="table"}. The Newcastle-Ottawa Scale (NOS) scores of all included studies ranged from 5 to 8 stars. All studies conformed to the Hardy--Weinberg equilibrium (HWE).

![Selection for eligible publications included in this meta-analysis](oncotarget-08-25107-g001){#F1}

###### Characteristics of included studies

  Author and year   Country   SOC   Genotype methods   Ethnicity   Case   Control   HWE   NOS                   
  ----------------- --------- ----- ------------------ ----------- ------ --------- ----- ----- ----- ----- --- ---
  Mahmoundi_2014    Iran      HB    PCR                Caucasian   109    118       34    139   153   47    Y   6
  Yukselogu_2014    Turkey    HB    PCR-RFLP           Caucasian   79     58        24    88    85    24    Y   7
  Pechivanis_2007   Czech     HB    PCR                Caucasian   211    277       81    268   309   106   Y   7
  Samowitz_2006     USA       HB    PCR                American    718    657       197   829   906   229   Y   8
  Slattery_2004a    USA       PB    PCR                American    467    409       128   481   552   134   Y   6
  Slattery_2004b    USA       PB    PCR                American    325    343       562   421   423   139   Y   6

Abbreviations: SOC, source of control; PB, population-based controls; HB, hospital-based controls; HWE, Hardy--Weinberg equilibrium; NOS, Newcastle-Ottawa Scale.

Meta-analysis of IRS-2 gene rs1805097 polymorphism {#s2_2}
--------------------------------------------------

As shown in Table [2](#T2){ref-type="table"}, we detected an association between IRS-2 gene rs1805097 polymorphism and CRC risk (AA+GA vs. GG: OR, 0.91; 95% CI, 0.84--0.99, *P* = 0.022, Figure [2](#F2){ref-type="fig"}). Stratification analysis by ethnicity indicated that rs1805097 polymorphism was significantly associated with a decreased risk of CRC among Americans (AA+GA vs. GG: OR, 0.88; 95% CI, 0.80--0.97, *P* = 0.007, Figure [3](#F3){ref-type="fig"}), but not among other Caucasians. Stratification analysis of cancer type suggested that this polymorphism decreased the risk of colon cancer (AA+GA vs. GG: OR, 0.84; 95% CI, 0.76--0.94, *P* = 0.002, Figure [4](#F4){ref-type="fig"}). Regarding stratification analysis by source of control (SOC), no positive result was obtained in both population-based population and hospital-based population (Table [3](#T3){ref-type="table"}).

###### Meta-analysis of association between IRS-2 rs1805097 polymorphism and colorectal cancer risk

  Comparison     OR(95%CI)             *P*-value   *P* for heterogeneity   I^2^ (%)   Model
  -------------- --------------------- ----------- ----------------------- ---------- --------
  A vs. G        0.96(0.90,1.01)       0.132       0.939                   0          Fixed
  AA+GA vs. GG   **0.91(0.84,0.99)**   0.022       0.260                   23.2       Fixed
  AA vs. GG+GA   1.02(0.91,1.15)       0.721       0.695                   0          Fixed
  AA vs. GG      0.97(0.86,1.10)       0.669       0.994                   0          Fixed
  GA vs. GG      0.91(0.79,1.05)       0.189       0.055                   53.7       Random

![Forest plot shows odds ratio for the associations between rs1805097 polymorphism and CRC risk (AA+GA vs. GG)](oncotarget-08-25107-g002){#F2}

![Stratification analyses by ethnicity shows odds ratio for the associations between rs1805097 polymorphism and CRC risk (AA+GA vs. GG)](oncotarget-08-25107-g003){#F3}

![Stratification analyses of cancer type between rs1805097 polymorphism and CRC risk (AA+GA vs. GG)](oncotarget-08-25107-g004){#F4}

###### Summary of the subgroup analyses in this meta-analysis

  Comparison     Category      Category        Studies   OR (95% CI)           *P*-value   *P* for heterogeneity
  -------------- ------------- --------------- --------- --------------------- ----------- -----------------------
  A vs. G        Ethnicity     Caucasians      3         1.00(0.88,1.13)       0.943       0.913
                               Americans       3         0.94(0.88,1.01)       0.093       0.939
                 Cancer type   mixed           3         1.00(0.88,1.13)       0.943       0.913
                               Colon cancer    2         0.93(0.86,1.01)       0.078       0.696
                               Rectal cancer   1         0.98(0.85,1.13)       0.772       \<0.001
                 SOC           HB              4         0.96(0.89-1.04)       0.350       0.892
                               PB              2         0.94(0.86-1.04)       0.218       0.472
  AA+GA vs. GG   Ethnicity     Caucasians      3         1.01(0.85,1.20)       0.884       0.519
                               Americans       3         **0.88(0.80,0.97)**   0.007       0.198
                 Cancer type   mixed           3         1.01(0.85,1.20)       0.884       0.519
                               Colon cancer    2         **0.84(0.76,0.94)**   0.002       0.499
                               Rectal cancer   1         1.02(0.84,1.23)       0.867       \<0.001
                 SOC           HB              4         0.92(0.83,1.02)       0.125       0.358
                               PB              2         0.89(0.79,1.01)       0.082       0.076
  AA vs.GA+ GG   Ethnicity     Caucasians      3         0.96(0.75,1.22)       0.732       0.625
                               Americans       3         1.04(0.91,1.20)       0.541       0.422
                 Cancer type   mixed           3         0.96(0.75,1.22)       0.732       0.625
                               Colon cancer    2         1.10(0.94,1.29)       0.238       0.825
                               Rectal cancer   1         0.89(0.67,1.18)       0.414       \<0.001
                 SOC           HB              4         1.03(0.88,1.20)       0.704       0.674
                               PB              2         1.01(0.84,1.22)       0.920       0.225
  AA vs.GG       Ethnicity     Caucasians      3         0.98(0.76,1.27)       0.875       0.900
                               Americans       3         0.97(0.84,1.12)       0.687       0.898
                 Cancer type   mixed           3         0.98(0.76,1.27)       0.875       0.900
                               Colon cancer    2         0.99(0.84,1.17)       0.904       0.957
                               Rectal cancer   1         0.91(0.68,1.23)       0.549       \<0.001
                 SOC           HB              4         0.99(0.84,1.17)       0.882       0.975
                               PB              2         0.95(0.78,1.16)       0.662       0.718
  GA vs.GG       Ethnicity     Caucasians      3         1.01(0.82,1.24)       0.929       0.292
                               Americans       3         0.91(0.79,1.05)       0.099       0.062
                 Cancer type   mixed           3         1.01(0.82,1.24)       0.929       0.292
                               Colon cancer    2         0.81(0.72,0.90)       \<0.001     0.428
                               Rectal cancer   1         1.05(0.86,1.29)       0.635       \<0.001
                 SOC           HB              4         0.93(0.78,1.11)       0.404       0.145
                               PB              2         0.89(0.65,1.22)       0.475       0.021

Abbreviations: SOC, source of control; PB, population-based controls; HB, hospital-based controls.

We assessed sensitivity by omitting each study once at a time in every genetic model for rs1805097 polymorphism. Our data indicated that the findings of this meta-analysis were stable and trustworthy (AA vs. GG+GA, Figure [5](#F5){ref-type="fig"}). Both Egger\'s and Begg\'s tests (A vs. G, Figure [6](#F6){ref-type="fig"}) revealed that there was no obvious publication bias for rs1805097 polymorphism (data not shown).

![Sensitivity analysis about rs1805097 polymorphism and CRC risk (AA vs. GG+GA)](oncotarget-08-25107-g005){#F5}

![Begg\'s tests for rs1805097 polymorphism and CRC risk (A vs. G)](oncotarget-08-25107-g006){#F6}

DISCUSSION {#s3}
==========

In this current meta-analysis, we found that IRS-2 gene rs1805097 polymorphism decreased the risk of CRC. Stratification analysis revealed that rs1805097 polymorphism was associated with a decreased risk of CRC among Americans. In addition, stratification analysis of cancer type suggested that rs1805097 polymorphism decreased the risk of colon cancer.

Insulin, a hormone, controls the energy homeostasis by functioning on target tissues. Insulin increases cell proliferation and decreases apoptosis \[[@R4], [@R13]\]. Many studies indicated that hyperinsulinemia and insulin resistance (IR) are involved in the etiology of CRC \[[@R14]\]. Hyperinsulinemia interacting with obesity was an important risk factor for CRC \[[@R4], [@R14]\]. Larsson et al. found a relationship between diabetes and increased risk of CRC \[[@R13]\]. Insulin-like growth factor (IGF), insulin-like growth factor binding proteins (IGFBPs), insulin and IRS play crucial roles in the initiation of cell growth and CRC proliferation \[[@R15], [@R16]\]. IRS-2 mediates the major metabolic, proliferative, and antiapoptotic functions of the IGF1 \[[@R17], [@R18]\]. IRS-2 gene variants were reported to be involved in the modulation of IRS-1 or IRS-2 functions and could be relevant to colorectal tumorigenesis \[[@R19]\]. So far, a number of studies \[[@R8]--[@R12]\] investigated the association between IRS-2 gene rs1805097 polymorphism and CRC risk. However, these studies yield contradictory results. Thus, we conducted this current meta-analysis.

Previous meta-analysis by Hu et al. indicated that IRS-2 rs1805097 polymorphism was not associated with CRC risk \[[@R20]\]. They only included 4 studies. To date, two studies \[[@R9], [@R11]\] have been reported in recent years since the meta-analysis \[[@R20]\]. In analysis of all included studies, our meta-analysis found that rs1805097 polymorphism was associated with decreased CRC risk. We believed that Hu et al. falsely extracted the genotype numbers of cases and controls from an American study \[[@R8]\]. Actually, the genotype numbers of this study were as following: colon cancers (GG=467, GA=409, AA=128), controls (GG=481, GA=552, AA=134); rectal cancers (GG=325, GA=343, AA=98), controls (GG=421, GA=423, AA=139). In addition, the above false data explained the reason why the HWE value in this American study was wrong \[[@R8]\]. According to our data, the study \[[@R8]\] by Slattery et al. conformed to HWE. We also conducted stratification analysis of cancer type, which was not performed by Hu et al. \[[@R20]\]. Our data suggested that rs1805097 polymorphism was associated with a decreased risk of colon cancer.

We believe our meta-analysis more robust than previous meta-analysis by Hu et al. \[[@R20]\]. First, we included 2 extra studies and the sample size of this meta-analysis was larger than previous meta-analysis. Second, sensitivity analysis indicated that our data about rs1805097 polymorphism were trustworthy and stable. Third, the power analysis indicated that this meta-analysis had a power of 96.9% to detect the effect of rs1805097 polymorphism on CRC risk with an OR of 0.91.

Several potential limitations should be addressed in this meta-analysis. First, due to limited data, we could not investigate the association between CRC and other potential factors, such as age and sex. Second, our results were based on unadjusted estimates for confounding factors, which might have affected the final findings. Third, we could not assess potential gene-gene and gene-environment interactions because of the lack of relevant data. Fourth, the sample size of this meta-analysis is not very large, and the number of included studies is small. Fifth, the findings of the stratified analyses should be interpreted with caution because of limited sample sizes.

In conclusion, this meta-analysis indicates that IRS-2 gene rs1805097 polymorphism decreased the risk of CRC. Further studies are necessary to validate whether rs1805097 polymorphism contributes to CRC susceptibility in other ethnic groups.

MATERIALS AND METHODS {#s4}
=====================

Literature search and inclusion criteria {#s4_1}
----------------------------------------

We systematically searched the PubMed and Embase to identify studies through August 19, 2016. The following search terms were used: "cancer," ''carcinoma,'' "neoplasm,'' ''tumor,'' ''Insulin Receptor Substrate 2,'' ''IRS-2,'' and ''IRS 2′'. No restrictions were placed on the literature search. Reference lists were identified by hand screening. The identified studies conformed to the following criteria: (1) studies that evaluated the association between IRS-2 gene rs1805097 polymorphism and CRC risk, (2) study provided sufficient data to calculate the odds ratios (ORs) and 95% confidence intervals (CIs), (3) case-control study.

Data extraction and quality assessment {#s4_2}
--------------------------------------

Relevant information was carefully extracted from all eligible studies. The extracted information from all eligible studies including: name of first author, publication year, country of origin, ethnicity, genotype methods and genotype numbers of cases and controls. Two authors independently performed the extraction of data and assessed the study quality based on the NOS \[[@R21]\]. All disagreements were discussed and resolved with consensus.

Statistical analyses {#s4_3}
--------------------

All statistical analyses were performed using the Stata 11.0 software (StataCorp, College Station, TX, USA). ORs and 95%CIs were used to assess the strength of association between IRS-2 gene rs1805097 polymorphism and CRC risk. Stratification analyses were carried out by ethnicity, SOC and cancer type. When a Q test indicated *P* \< 0.1 or I^2^ \> 50% indicated heterogeneity across studies, a random-effect model was used. Otherwise, the fixed-effects model was applied \[[@R22]\]. Allele model, dominant model, recessive model, homozygous model, and heterozygous model were used in this meta-analysis. We performed leave-one-out sensitivity analysis to evaluate the stability of the overall results. We assessed the departure from the HWE in the controls using Pearson\'s χ2 test. Potential publication bias was assessed by Begger\'s and Egger\'s linear regression test \[[@R23]\]; *P* \< 0.05 was considered to indicate statistically significant. The power of this meta-analysis was calculated with a significant value of 0.05 \[[@R24]\].
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